Drug Trial Radar · NCT01629667
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
Last checked: Nov 20, 2026Latest source record: May 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
409
Actual
Start
Oct 2012
Primary completion
May 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 27, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 79 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
TralokinumabBiological
Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
TralokinumabBiological
Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
PlaceboOther
Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 52Time frame: Baseline and Week 52
Locations
45 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Phoenix, Arizona
Research Site
La Jolla, California
Research Site
Sacramento, California
Research Site
Tampa, Florida
Research Site
Winter Park, Florida
Research Site
Atlanta, Georgia
Research Site
Honolulu, Hawaii
Research Site
Chicago, Illinois
Research Site
Louisville, Kentucky
Research Site
Ann Arbor, Michigan
Research Site
Rochester, Minnesota
Research Site
Chesterfield, Missouri
Research Site
Summit, New Jersey
Research Site
Durham, North Carolina
Research Site
Hershey, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Charleston, South Carolina
Research Site
Nashville, Tennessee
Research Site
McAllen, Texas
Research Site
McKinney, Texas
Research Site
Salt Lake City, Utah
Research Site
Box Hill, Australia
Research Site
Camperdown, Australia
Research Site
Concord, Australia
Research Site
Darlinghurst, Australia
Research Site
Frankston, Australia
Research Site
Glen Osmond, Australia
Research Site
New Lambton, Australia
Research Site
Parkville, Australia
Research Site
Prahran, Australia
Research Site
Woodville South, Australia
Research Site
Edmonton, Alberta, Canada
Research Site
Vancouver, British Columbia, Canada
Research Site
Windsor, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Ashkelon, Israel
Research Site
Haifa, Israel
Research Site
Jerusalem, Israel
Research Site
Petah Tikva, Israel
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.